MoSys, Inc. is a fabless semiconductor company enabling leading equipment manufacturers in the networking and communications markets to support the continual increase in Internet users, data and services. The company's solutions eliminate critical data throughput and access bottlenecks in leading edge applications to deliver speed and intelligence on line cards and systems with aggregate rates above 100 Gigabits per second (Gbps). The resulting solutions improve performance and features while reducing system level power, area, pin count and economics. The massive increase in number of users, amount of data per user and more complex, real-time bandwidth-intensive services, such as video-on-demand, Internet protocol TV, peer-to-peer, Cloud Computing, Web 2.0 applications, and 3G/4G, are spurring the demand for higher data throughput. Service providers need innovative new technologies to manage quality of service and network security in addition to expanded monitoring, measurement and administration functions to satisfy high expectations in user experience. This means routers, switches, and communications equipment must support aggregate data rates in the 100s of Gbps with increased data processing per packet. In order to meet these requirements, data access and throughput bottlenecks between data processing elements and memory need to be solved. MoSys:registered: Bandwidth Engine family of ICs, with its combination of serial I/O, high-speed memory, efficient access, and intelligent offload drastically increases data accesses per second, removing these bottlenecks. MoSys' LineSpeed family is optimized to enable higher-density, lower-power data path connectivity as electrical interface rates transition from 10Gbps to 25Gbps, which is necessary to support 100G optical links. When combined with the packet processing offload capabilities of the Bandwidth Engine family of ICs, MoSys' solutions are enabling speed, density and intelligence in the network. MoSys is an ISO 9000 certified IC manufacturer and its Bandwidth Engine product has been qualified to meet carrier-grade reliability requirements.

Amazentis SA is a company headquartered in Lausanne, Switzerland. The firm engages in research and development of life sciences. It was founded in 2007 by Patrick Aebischer, Chris Rinsch and Pierre Landolt. Chris Rinsch has been the CEO since the company founding.\nThe company says this about itself: Amazentis is an innovative life sciences company employing today’s leading research and clinical science to develop the next generation of products targeting mitochondrial health for advanced nutrition. Amazentis has previously published its research on Mitopure™ Urolithin A in top peer reviewed scientific journals including Nature Medicine (doi:10.1038/nm.4132), Nature Metabolism (doi: 10.1038/s42255-019-0073-4), JAMA Network Open (doi:10.1001/jamanetworkopen.2021.44279) and European Journal of Clinical Nutrition (https://doi.org/10.1038/s41430-021-00950-1). The company has a global strategic partnership with Nestlé Health Science to expand the health applications of Mitopure™ linked to mitochondrial and cellular health.

RFS Pharma, LLC is a clinical-stage biopharmaceutical company founded by Dr. Raymond F. Schinazi to develop new drugs for the treatment of hepatitis infections as well as emerging viruses. Located in a laboratory facility in suburban Atlanta, RFS Pharma will continue to provide growth to the pharmaceutical industry in Georgia. RFS Pharma was incorporated in 2004 and in-licensed anti-hepatitis technology from Emory University in 2013. In addition to its own pipeline, RFS Pharma is actively seeking promising new drugs for in-licensing.

Part of Olin Corp., Blue Cube IP LLC is an American company that manufactures industrial organic chemicals.

Ciphergen Biosystems KK markets and supplies protein chip systems and services for clinical, research and process proteomic applications. The company was founded in January, 1999 and is headquartered in Yokohama, Japan.

Mitutoyo Corp. manufactures precision measurement instruments. Its products include micrometers, calipers, height measuring tools, precision sensor systems. Linear encoders, and dial gages. The company was founded by Yehan Numata on October 22, 1934 and is headquartered in Kawasaki, Japan.

Ramot at Tel Aviv University Ltd. operates as a technology transfer company of Tel Aviv University (TAU). It provides legal and commercial frameworks for inventions made by TAU faculty, students, and researchers. The firm licenses the university's intellectual property to third parties through agreements; facilitates collaborative research partnerships between business partners and TAU researchers; establishes a company; and forms joint ventures that promote TAU technologies. The company was founded in 1973 and is headquartered in Tel Aviv, Israel.

Macronix International Co., Ltd. engages in the research and development, manufacture, and sale of integrated devices in non-volatile memory market. It focuses on NOR flash, NAND flash, and Read-only memory (ROM) products. The company products includes Octa, wide range VCC, serial NOR, parallel NOR, SLC NAND, and serial NAND flash. Its products are used in consumer, communication, computing, automotive, networking, and other segment markets. The company was founded by Miin Chyou Wu on December 9, 1989 and is headquartered in Hsinchu, Taiwan.

Sartorius Stedim North America, Inc., part of Sartorius AG, is an American company located in Bohemia, NY. The firm supplies pharmaceutical and laboratory equipment.

Jiangsu Baona Electromagnetic New Material Co., Ltd., established on 2013-05-31, Business scope includes metal magnetic components,Research and Development of Optoelectronic Devices,manufacture;Switchgear,Bridge,busbar,Electrical machinery and equipment,hardware,Rubber products processing,manufacture;Metal Material Sales;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts enterprises to operate or prohibits import and export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Toyo Kanetsu KK is a logistics solution business that provides planning, designing, manufacturing, construction, and sales of logistics systems and information systems. It is a machinery manufacturing company. They provide industrial machinery, construction, environmental research and analysis, maintenance, and management of environmental measurement equipment.

Zuoda New Material Technology Group Co., Ltd., established on 2013-11-13, Business scope includes technology development,technical consulting,Technical Services,technology transfer;Sell ​​self-developed products,building materials;Import and export,Agent import and export,Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Tableau Software is a company on a mission. They help people see and understand their data. After a highly successful IPO in 2013, Tableau has become a market-defining company in the business intelligence industry. Their culture is casual and high-energy. They are passionate about their product and their mission and they are loyal to each other and their company. They value work/life balance, efficiency, simplicity, freakishly friendly customer service, and making a difference in the world!

Atlantic Zeiser is a leading provider of sophisticated serialization, personalization, customization and track & trace solutions. Atlantic Zeiser is a competent, innovative and reliable partner that helps companies, government agencies or institutions face new challenges.

AIT Foreign Language Center is a language learning institute.

Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the manufacture, research and development of active pharmaceutical ingredients (API). Its products include pain management for skeletal muscle pain & migraine, immunosuppressant for reducing immune activity after organ transplant, antifungal such as fluconazole, caspofungin & micafungin, oncology that act against cancers, lowering cholesterol & chronic heart disease and other APIs for lowering cholesterol and anti diabetic drugs. The company was founded on May 19, 1964 and is headquartered in New Taipei, Taiwan.

3M Innovative Properties Co. acquires and manages intellectual property right. It engages in the acquisition and ownership of the intellectual property rights to the products designed and manufactured by its parent company 3M Corporation. The company was founded on May 10, 1999 and is headquartered in Roseville, MN.

Idera Pharmaceuticals, Inc., a biotechnology company, discovers and develops DNA- and RNA-based drug candidates for the treatment of infectious diseases, autoimmune and inflammatory diseases, cancer, and asthma and allergies, and for use as vaccine adjuvants. The company designs and creates proprietary Toll-Like Receptors (TLR) to modulate immune responses, including TLR agonist, a compound that stimulates an immune response through the targeted TLR; and TLR antagonist, a compound that blocks activation of an immune response through the targeted TLR. Its drug candidates include IMO-2125, a TLR9 agonist, which is in Phase 1 clinical trial for hepatitis C virus infection; and TLR7, 8, and 9 agonists that are in research stage for viral diseases. The company also develops IMO-3100, a dual TLR7/TLR9 antagonist, which is in preclinical development stage for autoimmune and inflammatory diseases, such as lupus, rheumatoid arthritis, multiple sclerosis, psoriasis, and colitis. In addition, its drug candidates also comprise TLR7 and TLR8 agonists that are in research stage for solid tumor cancers. The company has a licensing and collaboration agreement with Merck KGaA to research, develop, and commercialize TLR9 agonists for the treatment of cancer, excluding cancer vaccines; a license and research collaboration agreement with Merck & Co., Inc. to research, develop, and commercialize therapeutic and prophylactic vaccine products containing its TLR7, 8, and 9 agonists in the fields of cancer, infectious diseases, and Alzheimer's disease; and a research collaboration and option agreement, and a license, development, and commercialization agreement with Novartis International Pharmaceutical, Ltd. to discover, develop, and commercialize TLR9 agonists for the treatment of asthma and allergies. The company was founded in 1989 and is based in Cambridge, Massachusetts.